Pancreatic Cancer Research

ResearcherIRCCS Ospedale San RaffaeleActive in the last 2 years

Erica Dugnani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7701-7535; OpenAlex author ID A5029013381. Sources: OpenAlex.

Their work

Papers
18 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 4 papers · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers

Papers 18

  1. Establishment of a Transplantation Model of PDAC-Derived Liver Metastases. First author DOI 10.1245/s10434-024-15514-3↗
  2. ASO Author Reflections: Bridging the Gap in PDAC Research: The Intraportal Model as a Platform for Studying Preclinical Liver Metastasis. First author DOI 10.1245/s10434-024-15655-5↗
  3. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06685-2↗
  4. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003549↗
  5. A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/ijms231810663↗
  6. B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2020.1794359↗
  7. Circulating Chromogranin A Is Cleaved Into Vasoregulatory Fragments in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.613582↗
  8. Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer. First author DOI 10.1007/s00592-019-01335-4↗
  9. Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with c… Co-author DOI 10.1016/j.pan.2018.09.006↗
  10. Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. Co-author DOI 10.1093/carcin/bgy094↗
  11. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. Co-author DOI 10.3233/cbm-181218↗
  12. A preoperative score to predict early death after pancreatic cancer resection. First author DOI 10.1016/j.dld.2017.06.012↗
  13. Modeling the Iatrogenic Pancreatic Cancer Risk After Islet Autotransplantation in Mouse. Co-author DOI 10.1111/ajt.14360↗
  14. Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-015-2932-3↗
  15. Diabetes associated with pancreatic ductal adenocarcinoma is just diabetes: Results of a prospective observational study in surgical patients. Co-author DOI 10.1016/j.pan.2016.08.005↗
  16. (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. First author DOI 10.1158/1078-0432.ccr-15-1722↗
  17. Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study. First author DOI 10.1371/journal.pone.0166008↗
  18. Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells. Co-author DOI 10.1007/s00216-013-6880-7↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lorenzo Piemonti · 18 shared papers, 2013–2024 · strength 1.63
  2. Claudio Doglioni · 11 shared papers, 2016–2024 · strength 0.97
  3. Valentina Pasquale · 10 shared papers, 2016–2022 · strength 0.74
  4. Michele Reni · 9 shared papers, 2016–2022 · strength 0.66
  5. Massimo Falconi · 9 shared papers, 2016–2023 · strength 0.65
  6. Gianpaolo Balzano · 8 shared papers, 2016–2022 · strength 0.58
  7. Benedetta Ferrara · 3 shared papers, 2022–2024 · strength 0.57
  8. Marco Schiavo Lena · 3 shared papers, 2023–2024 · strength 0.52
  9. Daniela Liberati · 8 shared papers, 2016–2019 · strength 0.52
  10. Paolo Riccardo Camisa · 2 shared papers, 2024 · strength 0.40
  11. Stefano Crippa · 3 shared papers, 2017–2023 · strength 0.26
  12. Vincenzo Corbo · 2 shared papers, 2022–2023 · strength 0.22
  13. Vito Lampasona · 3 shared papers, 2016–2018 · strength 0.20
  14. Maria Pia Protti · 2 shared papers, 2020 · strength 0.18
  15. Francesco De Sanctis · 2 shared papers, 2018–2022 · strength 0.17
  16. Francesco Novelli · 2 shared papers, 2013–2023 · strength 0.15
  17. Florent Ginhoux · 1 shared paper, 2023 · strength 0.11
  18. Nicoletta Caronni · 1 shared paper, 2023 · strength 0.11
  19. Paola Cappello · 1 shared paper, 2023 · strength 0.11
  20. Silvia Brugiapaglia · 1 shared paper, 2023 · strength 0.11
  21. Renato Ostuni · 1 shared paper, 2023 · strength 0.11
  22. Matteo Fassan · 1 shared paper, 2022 · strength 0.10
  23. Vincenzo Bronte · 1 shared paper, 2022 · strength 0.10
  24. Chiara Musiu · 1 shared paper, 2022 · strength 0.10
  25. Rita Teresa Lawlor · 1 shared paper, 2022 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.